Company profile: Certara
1.1 - Company Overview
Company description
- Provider of biosimulation software and technology to accelerate medicines, including Phoenix WinNonlin for non-compartmental analysis, toxicokinetic and PK/PD modeling; Simcyp Simulator for physiologically based pharmacokinetic modeling; Pinnacle 21 for clinical data standardization and compliance; D360 for data access and integrated analysis; Certara Integral data repository; PK Submit for automating CDISC domains in NCA.
Products and services
- Simcyp Simulator: PBPK-based platform that models and predicts drug behavior in diverse populations, employing physiologically based pharmacokinetic modeling to forecast population-specific outcomes
- Phoenix WinNonlin: software-based application executing non-compartmental analysis, toxicokinetic modeling, and integrated pharmacokinetic/pharmacodynamic modeling for study datasets across research workflows
- Pinnacle 21: compliance-focused suite that standardizes clinical data and streamlines clinical trial submissions, supporting data conformance throughout submission preparation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Certara
Reverie Labs
HQ: United States
Website
- Description: Provider of machine learning-driven preclinical drug development solutions, applying supervised deep learning, virtual screening, computational chemistry, and algorithmic molecular generation for lead discovery and optimization. Offers molecular property prediction (on-target binding, toxicity, ADMET), rich representations for small molecules and proteins, and a pipeline of wholly-owned and partner-developed drug candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverie Labs company profile →
Mindprint Solutions
HQ: Canada
Website
- Description: Provider of software system implementation, serving as the partner that can make the difference, empowering organizations with a highly effective system rather than wasted resources in a failed implementation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mindprint Solutions company profile →
Aitia
HQ: United States
Website
- Description: Provider of Causal AI and digital twin-based drug discovery solutions. Offers Gemini Digital Twins—computational disease models that simulate genetic and molecular interactions to identify novel drug targets and patient subpopulations—and Causal AI Drug Discovery leveraging multi-omic data to accelerate development of new therapies for neurodegenerative diseases and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aitia company profile →
EncrypGen
HQ: United States
Website
- Description: Provider of next-generation software for genomic data, empowering patients and donors and facilitating health, business, and science.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EncrypGen company profile →
MedSciNet
HQ: Sweden
Website
- Description: Provider of tailor-made database applications for clinical trials, built and managed by an internet company, supporting well-organised, high-quality medical data to create preconditions for clinical researchers and other professionals to achieve medical breakthroughs and innovations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedSciNet company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Certara
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Certara
2.2 - Growth funds investing in similar companies to Certara
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Certara
4.2 - Public trading comparable groups for Certara
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →